OSE Immunotherapeutics SA

OSE Immunotherapeutics SA is a clinical-stage biotechnology company headquartered in Nantes, France, dedicated to developing and partnering first-in-class immunotherapies. The company's core mission revolves around controlling the immune system to address significant unmet medical needs in immuno-oncology and immuno-inflammation.

OSE Immunotherapeutics boasts a diversified clinical pipeline featuring several key product candidates. These include Tedopi®, a T-cell-based cancer vaccine, OSE-279, an anti-PD1 antibody, and Lusvertikimab (OSE-127), a humanized monoclonal antibody targeting the IL-7 receptor. The pipeline also comprises partnered assets such as FR-104/VEL-101 (anti-CD28 mAb), BI 765063/BI 770371 (anti-SIRPα mAb), and OSE-230 (ChemR23 agonist mAb). The company leverages proprietary drug discovery platforms, including Pro-resolutive mAb, Myeloid Checkpoint, and BiCKI® systems, to drive its research and development efforts in immuno-oncology and autoimmune diseases.

Recent developments highlight OSE Immunotherapeutics' strategic focus and advancements. In March 2026, Marc Le Bozec was confirmed as the Chief Executive Officer, with Thomas Gidoin appointed Deputy CEO and Aurore Morello as Chief Scientific Officer in April 2026, strengthening the leadership team. The company received an FDA Orphan Drug Designation for pegrizeprument (VEL-101), developed in partnership with Veloxis Pharmaceuticals, in April 2026, for anti-rejection treatment. Tedopi® was also selected for presentation at the ASCO 2026 meeting. OSE Immunotherapeutics has established strategic partnerships with major pharmaceutical companies like AbbVie and Boehringer Ingelheim, contributing to its market positioning as an innovative player in the immunotherapy landscape.

Latest updates

OSE Immunotherapeutics Burns Through Cash, Delays Audit Amid Governance Overhaul

Event summary

  • OSE Immunotherapeutics reported a €37.7 million net loss for full-year 2025, reversing a €37.4 million profit in 2024.
  • The company's cash position dwindled from €64.2 million at the end of 2024 to €22.7 million as of December 31, 2025, and further to €17.0 million by March 31, 2026, projecting a runway until early Q4 2026.
  • The filing of the 2025 Universal Registration Document has been postponed to May 28, 2026, due to ongoing audit procedures and financing uncertainties.
  • Increased operating expenses, particularly legal fees related to a governance overhaul following a shareholder vote in September 2025, contributed to the loss.

The big picture

OSE Immunotherapeutics' financial performance reflects a shift from one-time gains in 2024 to increased investment in its pipeline, particularly the Tedopi Phase 3 trial. The delayed audit and financing uncertainties highlight the challenges faced by smaller biotech companies reliant on partnerships and capital markets. The governance shakeup underscores the pressures the company is facing to deliver value and maintain investor confidence.

What we're watching

Financing Risk
The company's stated need for additional financing to extend its runway beyond early Q4 2026 raises concerns about its ability to secure capital on favorable terms, potentially impacting development timelines.
Governance Stability
The recent governance overhaul and legal proceedings suggest ongoing instability that could distract management and hinder strategic execution.
Clinical Trial Progress
The success of the ongoing Phase 3 trial of Tedopi – Artemia will be critical to demonstrating clinical value and attracting potential partners or investors.

OSE Immunotherapeutics Sees Pegrizeprument Advance with FDA Orphan Drug Designation

Event summary

  • OSE Immunotherapeutics’ partner, Veloxis Pharmaceuticals, received FDA Orphan Drug Designation for pegrizeprument (VEL-101) for heart transplant rejection prevention.
  • This designation follows a similar grant in January 2026 for liver transplant rejection prevention.
  • Pegrizeprument was originally discovered and developed by OSE and licensed to Veloxis in 2021 for all transplant indications.
  • The FDA Orphan Drug Designation program provides incentives for developing treatments for rare diseases affecting fewer than 200,000 people in the US.

The big picture

The Orphan Drug Designation provides a valuable regulatory and financial incentive for Veloxis, potentially accelerating development and increasing market exclusivity for pegrizeprument. This highlights the growing focus on treatments for transplant rejection, a significant unmet medical need with a substantial, albeit niche, patient population. The deal structure, where OSE licensed the asset, demonstrates a common strategy for smaller biotech firms to monetize early-stage discoveries through partnerships.

What we're watching

Clinical Trial Progress
The speed of ongoing clinical trials will dictate the timeline for potential regulatory approvals beyond this designation, and the ultimate commercial viability of pegrizeprument.
Commercial Execution
Veloxis’ ability to successfully manufacture and commercialize pegrizeprument will be critical, given its global responsibility for the product’s lifecycle.
Royalty Structure
The financial terms of the licensing agreement between OSE and Veloxis, particularly royalty payments, will determine the extent of OSE’s financial benefit from pegrizeprument’s success.
CID: 3578